India's $200bn Pharma Opportunity - Scaling the Patent Cliff

Exploring the huge market opportunity opening up in Pharma due to the impending patent cliff.

You can download the PDF report here.

---

DISCLAIMER

SEBI Registered Corporate Research Analyst. Registration: Cupressus Enterprises Pvt Ltd (owner of Intelsense.in) - INH000013828.

Compliance Officer: Soumyadip Roy. Email: equity@intelsense.in

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

This report is issued by Intelsense.in, which is regulated by the SEBI.

References to "Cupressus Enterprises Pvt Ltd" or “Intelsense.in” in this report shall mean Cupressus Enterprises Pvt Ltd unless otherwise stated. This report is prepared and distributed for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by Intelsense.in to be valid when published. The report also contains information provided by third parties. The source of such information will usually be disclosed in the report. Whilst Intelsense.in has taken all reasonable steps to ensure that this information is correct, it does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and Intelsense.in does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

This report does not regard the specific investment objectives, financial situation, and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realised. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which Intelsense.in believe is reliable. Intelsense.in, Cupressus Enterprises Pvt Ltd or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice.